Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
4 hedge funds and large institutions have $3.59M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCI
Jet Capital Investors
New York
|
+$3.59M |
Top Sellers
BMY.RT Hedge Fund Activity: Q4 2021 in Review
4 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q4 2021, worth a combined $3.59M.
Fund positioning in BMY.RT was balanced in Q4 2021: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Jet Capital Investors, opening a new position worth an estimated $3.59M.
- 4 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $3.59M of Bristol-Myers Squibb Company Contingent Value Rights stock for Q4 2021.
- 1 fund opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q4 2021 and 1 closed out, a net change of 0 holders.
- The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q4 2021 was Jet Capital Investors, an estimated $3.59M added.
Based on aggregated 13F filings for Q4 2021.